Friday, December 1, 2023
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Director of General Cardiology
Cardiovascular Division
Brigham and Women's Hospital
Investigator, TIMI Study Group
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts, United States
Professor of Pharmacy Practice
University of Connecticut School of Pharmacy
Director of UCONN/Hartford Hospital Evidence Based Practice Center
Hartford, Connecticut, United States
Head of Complications Research
Steno Diabetes Center Copenhagen
Professor of the Department of Clinical Medicine
University of Copenhagen
Gentofte, Denmark
Associate Director, Accreditation and Compliance, Medscape, LLC
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories
This activity is intended for cardiologists, primary care physicians, and neurologists.
The goal of this activity is to provide the latest information on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF), especially regarding the advantages of using NOACs in patients with reduced renal function.
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Director of General Cardiology
Cardiovascular Division
Brigham and Women's Hospital
Investigator, TIMI Study Group
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts, United States
Professor of Pharmacy Practice
University of Connecticut School of Pharmacy
Director of UCONN/Hartford Hospital Evidence Based Practice Center
Hartford, Connecticut, United States
Head of Complications Research
Steno Diabetes Center Copenhagen
Professor of the Department of Clinical Medicine
University of Copenhagen
Gentofte, Denmark
Associate Director, Accreditation and Compliance, Medscape, LLC
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott Laboratories
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 5/29/2020
Valid for credit through: 5/29/2021, 11:59 PM EST
processing....
The goal of this activity is to provide the latest information on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fibrillation (AF), especially regarding the advantages of using NOACs in patients with reduced renal function.
Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.
